Systemic Juvenile Idiopathic Arthritis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2015-10-15
Clinical Trial Update: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) [Phase 3]
The Phase 3 open-label safety and tolerability study of canakinumab in active systemic Juvenile Idiopathic Arthritis has been withdrawn.